Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm…
We haven't written up this one. South China Morning Post has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics statnews.com
- Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback scmp.com
- FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting endpoints.news
- FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector ft.com
- FDA declines approval of Summit’s lung cancer treatment seekingalpha.com